Aslan
ClosedSingapore, Singapore · Founded 2010 · $76.0M raised
- Headquarters
- Singapore, Singapore
- Employees
- 11–50
- Founded
- 2010
- Business Model
- B2B
- Website
- aslanpharma.com
- Total Funding
- $76.0M
- Last Round
- $20.0M Venture RoundMar 2023
- Rounds
- 5
About
ASLAN Pharmaceuticals is a Singapore-based clinical-stage biopharmaceutical company developing immunotherapies and targeted agents for indications including atopic dermatitis and autoimmune conditions. Its lead candidate, eblasakimab, is an antibody targeting the IL-13 receptor. Founded in 2010 by Carl Firth, ASLAN listed on Nasdaq in 2018 and has raised capital across venture, pre-IPO and post-IPO rounds from investors such as Accuron Technologies (a Temasek subsidiary), BVF Partners and K2 HealthVentures.
Summary
Aslan is a Biotech company based in Singapore, Singapore, founded in 2010. It has raised $76.0M in total across 5 rounds, most recently a $20.0M Venture Round round in Mar 2023.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2023
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...